

Clozapine - General Practitioner Information Sheet

Clozapine is an antipsychotic used in the treatment of schizophrenia when other antipsychotics have not worked. It may also be used for psychotic disorders occurring in Parkinson's disease when standard treatment has failed. Clozapine is classed as a **RED** drug which means it must only be prescribed by secondary care mental health services and prescribing responsibility will not transfer to GPs under any circumstances.


Please ensure information regarding clozapine is added to the practice patient medical record for each patient, to enhance patient safety and minimise the following potential risks:




- Inadvertent co-prescribing of interacting medications
- The potential to miss side effects or not attribute them to clozapine therapy
- Clozapine being missed on admission if admitted to another Trust. Hospitals are currently not able to add hospital-only prescribed medicines directly onto a patients summary care record

It is not necessary to record accurate details of the dose on your system, as details of this may change frequently, selection of a clozapine formulation with a freehand note to state "dose managed by X clinic" is sufficient.

Since clozapine can cause neutropenia and agranulocytosis regular blood tests are required. The usual monitoring schedule is:



A traffic light system is used to direct action in response to white blood cell levels:



Patients who develop signs of infection such as sore throat and raised temperature are advised to contact their GP or member of the mental health team.

GPs should check FBC and notify the mental health team.

Brand

TEVV has standardised on Clozaril® as the brand of clozapine used across the Trust. Blood monitoring is co-ordinated by Mylan through their Clozaril® Patient Monitoring Service (CPMS). However, patients with swallowing difficulties may be prescribed Denzapine® liquid or Zaponex® orodispersible tablets – blood monitoring for these patients is co-ordinated by Britannia Pharmaceuticals and Leyden Delta through their Denzapine® Monitoring System (DMS) and Zaponex Treatment Access System (ZTAS) respectively.

Title:	Clozapine – GP Information Sheet	Date of Approval	26 November 2020
Protocol Number	PHARM-0143-v5	Date of Review	30 April 2024

Side effects and monitoring

While outcomes of clozapine treatment are good, side effects are common. Unfortunately clozapine is associated with a range of troublesome side-effects some of which can have a profound effect on a patient's on-going physical health. The benefits of clozapine can take up to one year to be realised. During this period intensive support may be required to ensure treatment is optimised by titration to therapeutic doses, management of side effects, checking and resolving adherence issues. Some side effects occur in the first few weeks of treatment and usually wear off. Others persist and can have on-going effects on physical health or indicate serious problems requiring urgent action.



GPs should be aware of clozapine side effects so that physical health problems can be appropriately managed, cardiovascular and metabolic risk factors reduced and patient safety improved.

Clozapine and smoking: In smokers, metabolism of clozapine is significantly increased and so plasma clozapine levels are reduced. On cessation of smoking, plasma clozapine levels can rise dramatically (up to 70%) and only achieve steady state approximately 7-10 days after smoking cessation. If patients change their smoking habit including switching to an e-cigarette or starting nicotine replacement therapy the mental health team must be advised so that plasma levels can be monitored and dose adjustments made.



Clozapine and constipation: All patients on clozapine must be monitored and treated for constipation. Clozapine-induced gastrointestinal hypomotility is probably less well recognised but can progress to severe and fatal bowel obstruction (see side effect table for more information).

Side effect	Management
Agranulocytosis This is a potentially life-threatening situation and should be closely watched for. It occurs most frequently in the first 18 weeks of treatment.	The possibility of neutropenia should be considered in patients who present with symptoms such as fever, chills, sore mouth, sore throat or infection. Check FBC. If the white cells are all normal or raised, treat with an anti-pyretic and antibiotics (see interactions) if indicated. If any of the white cells are LOWERED or if there is ANY concern, contact the Consultant Psychiatrist or on-call doctor if out of hours.
Increased Heart Rate and Other Cardiac Symptoms Tachycardia very common in early stages of treatment, but usually benign. Sudden deaths associated with myocarditis have occurred in some patients; non-specific cardiac symptoms in a patient on clozapine should be thoroughly investigated.	Tachycardia, if persistent at rest and associated with fever, hypotension or chest pain, may indicate myocarditis. Referral to cardiologist advised. Benign sinus tachycardia can be treated with atenolol.
Constipation Very important to recognise and treat, as if left untreated can progress to intestinal obstruction or faecal impaction. This can be a chronic and serious problem, even life threatening http://www.wales.nhs.uk/sites3/documents/428/RW%20-%20CPhO%20Letter%20clozapine.pdf	Enquire about bowel function routinely and advise patient regarding exercise, fluids and high fibre diet. Symptoms of constipation should be treated with regular laxatives, bulk forming laxative (Fybogel) and if necessary a stimulant laxative (senna) are advised. Inform the mental health team if constipation persists. Avoid adding drugs that may cause constipation as a side effect e.g. antimuscarinic medicine.
Hypersalivation This usually occurs in the initial stages of treatment especially at night, but tolerance can develop.	Prop pillows up at night, towel on pillow and chew sugar-free gum. If troublesome patient may be prescribed hyoscine hydrobromide 300mcg (Kwells) usually at night, but can be given up to a maximum of three times daily. Encourage adequate fluid intake. For extreme hypersalivation refer back to psychiatrist.
Seizures Clozapine is associated with seizures and this can be dose related. At doses above 600mg daily there is a greatly increased incidence of developing seizures.	Refer urgently to Consultant Psychiatrist. Carbamazepine should not be prescribed.
Weight gain Usually during the first year of treatment. It is common and often profound (>10 kg)	Dietary counselling and lifestyle advice is essential.

In addition to the mandatory FBC monitoring described above, it is also possible to monitor clozapine serum levels, this will be done by the patient's usual clozapine clinic / mental health team and may be useful in the following circumstances:

- To assess **medication adherence** or to assess patients where there has been a **poor response**
- With **increasing age**, to inform dosage adjustments
- Where a patient has **pneumonia or other serious infection**
- To monitor the effect of **changes in smoking habit** including switching to an e-cigarette/NRT (see above)
- To diagnose dose-related adverse effects, especially if related to **changes in smoking habit**, where **drug-drug interactions** are a possibility or where, for example, **significant weight loss** may have affected the volume of distribution.
- Investigating suspected clozapine self-poisoning or clozapine toxicity
- Where the total daily dose is > 600mg, to assess the need for anticonvulsant prophylaxis
- To inform an annual review of treatment, where clinically indicated
- To provide a baseline for all service users transferred into TEVV on clozapine, to allow for informed, continued safe prescribing

Title:	Clozapine – GP Information Sheet	Date of Approval	26 November 2020
Protocol Number	PHARM-0143-v5	Date of Review	30 April 2024

Interactions with Clozapine

The following are the most common drug interactions (Taken and abridged from SPC for Clozaril Updated April 2020):

Drug	Interactions	Comments
Bone marrow suppressants (e.g. carbamazepine, chloramphenicol), sulphonamides (e.g. co-trimoxazole), pyrazolone analgesics (e.g. phenylbutazone), penicillamine, cytotoxic agents and long-acting depot injections of antipsychotics	Interact to increase the risk and/or severity of bone marrow suppression.	Clozapine must not be used concomitantly with other agents having a well known potential to suppress bone marrow function.
Benzodiazepines	Concomitant use may increase risk of circulatory collapse, which may lead to cardiac and/or respiratory arrest.	Caution advised if using together. Respiratory depression and collapse more likely to occur at start of this combination or when clozapine is added to an established benzodiazepine regimen.
Anticholinergics	Clozapine potentiates action of these agents through additive anticholinergic activity.	Observe patients for anticholinergic side-effects, e.g. constipation, especially when using to help control hypersalivation.
Antihypertensive agents	Clozapine can potentiate hypotensive effects of these agents due to sympathomimetic antagonistic effects.	Caution is advised. Patients should be advised of the risk of hypotension, especially during the period of initial dose titration.
Alcohol, MAOIs, CNS depressants, including narcotics and benzodiazepines	Enhanced central effects. Additive CNS depression and cognitive and motor performance interference when used in combination with these substances.	Caution is advised if clozapine is used concomitantly with other CNS active agents. Advise patients of the possible additive sedative effects and caution them not to drive or operate machinery.
Highly protein bound substances (e.g. warfarin and digoxin)	Clozapine may cause increase in plasma concentration of these substances due to displacement from plasma proteins.	Patients should be monitored for the occurrence of side effects associated with these substances, and doses of the protein bound substance adjusted, if necessary.
Antibiotics such as erythromycin and ciprofloxacin	Can elevate clozapine levels	Avoid combination if possible. Consider closer monitoring involving FBCs
Phenytoin	Addition of phenytoin to clozapine regimen may cause a decrease in the clozapine plasma concentrations.	If phenytoin must be used, the patient should be monitored closely for a worsening or recurrence of psychotic symptoms. Consider measuring serum clozapine to ensure therapeutic levels are maintained.
Lithium	Concomitant use can increase the risk of development of neuroleptic malignant syndrome (NMS).	Observe for signs and symptoms of NMS.
CYP1A2 inhibiting substances (e.g. fluvoxamine, caffeine, ciprofloxacin, hormonal contraceptives)	Concomitant use may increase clozapine levels	Potential for increase in adverse effects. Care is also required upon cessation of concomitant CYP1A2 inhibiting medications as there will be a decrease in clozapine levels.
CYP1A2 inducing substances (e.g. omeprazole)	Concomitant use may decrease clozapine levels	Potential for reduced efficacy of clozapine should be considered.

Title:	Clozapine – GP Information Sheet	Date of Approval	26 November 2020
Protocol Number	PHARM-0143-v5	Date of Review	30 April 2024